Rebee, a healthtech startup based in Singapore, has raised US$1.18 million in a seed funding round.

The investment was led by Paragon Ventures I, SEEDS Capital, 1337 Capital 1, The LAB9, and C-shark SG.

Rebee plans to use the funding to enhance its platform and to expand partnerships with healthcare providers in Singapore, Malaysia, and Australia.

The startup also aims to increase outreach to insurers and conduct further research on patient outcomes.

This funding is expected to help develop digital physiotherapy solutions across Southeast Asia.

Rebee provides a digital platform that integrates wearable sensors to support home-based recovery for musculoskeletal pain.

This technology aims to improve accessibility in physiotherapy by offering guided exercises, real-time feedback, and progress tracking.

🔗 Source: Rebee

🧠 Food for thought

1️⃣ Southeast Asia healthtech enters the age of focused seed investments

Rebee’s US$1.18 million seed round aligns with a significant shift in healthtech funding dynamics across Southeast Asia.

In 2024, early-stage investments represent nearly 40% of all healthcare deals, indicating strong momentum for innovative startups with focused solutions 1.

This contrasts with previous investment patterns that favored mega-deals ($100M+), which now represent only 2% of healthtech investments compared to much higher percentages during the 2021 boom 2.

The shift reflects investors’ more cautious approach following the 2021 overvaluations, with many companies that secured mega-deals subsequently failing, resulting in more companies going out of business than going public 2.

Healthtech investors are now prioritizing startups with clear value propositions and sustainable business models that address specific regional healthcare challenges, rather than pursuing the “growth at all costs” approach that characterized earlier funding waves.

2️⃣ Digital solutions addressing Southeast Asia’s critical healthcare accessibility gaps